| Identification | Back Directory | [Name]
PYR-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE-OH | [CAS]
217082-60-5 | [Synonyms]
Pyr-apelin-13
(Glp1)-Apelin-13
[PYR1]-APELIN-13
[pGlu1]-Apelin-13
PYR-RPRLSHKGPMPF-OH
[PE]APELIN-13, HUMAN, BOVINE
(GLP1)-APELIN-13, HUMAN, BOVINE
(PYR1)-APELIN-13 (HUMAN, BOVINE)
[PGLU1]APELIN (24-36), HUMAN, BOVINE
(PYR1)-APELIN-13 (HUMAN, BOVINE, MOUSE, RAT)
GLP-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE
PYR-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE
PGLU-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE
[Pyr1]-Apelin-13,XRPRLSHKGPMPF,[pGlu1]-Apelin-13, >98%
PYR-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE-OH
PYR-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE-OH USP/EP/BP
GLP-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE: GRPRLSHKGPMPF
5-Oxo-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-L-methionyl-L-prolyl-L-phenylalanine
L-Phenylalanine, 5-oxo-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-L-methionyl-L-prolyl- | [Molecular Formula]
C69H108N22O16S | [MDL Number]
MFCD01863147 | [MOL File]
217082-60-5.mol | [Molecular Weight]
1533.8 |
| Chemical Properties | Back Directory | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,Store in freezer, under -20°C | [form ]
Powder | [pka]
3.56±0.10(Predicted) | [color ]
White to off-white | [Water Solubility ]
Soluble to 1 mg/ml in sterile water | [Sequence]
Pyr-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe-OH | [InChIKey]
GGMAXEWLXWJGSF-PEWBXTNBSA-N |
| Hazard Information | Back Directory | [Uses]
The apelin gene encodes a pre-proprotein that is processed to generate bioactive peptides consisting of 36, 17, or 13 amino acids: apelin-36 , apelin-17, and apelin-13 , respectively. Apelin-13 is an endogenous ligand of the APJ receptor, activating this G protein-coupled receptor with an EC50 value of 0.37 nM. (Glp1)-Apelin-13 is a pyroglutamylated form of apelin-13, in that the N-terminal glutamine residue is cyclized to pyroglutamic acid. Like apelin-13, this compound is a potent APJ receptor agonist (EC50 = 0.30 nM). (Glp1)-Apelin-13 is the major apelin isoform in the plasma of healthy human subjects. It can have vasoconstrictor and antipyretic effects in vitro and in vivo. | [Definition]
ChEBI: P-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe is a thirteen-membered polypeptide consisting of p-Glu, Arg, Pro, Arg, Leu, Ser, His, Lys, Gly, Pro, Met, Pro and Phe residues joined in sequence. It has a role as an apoptosis inhibitor, a neuroprotective agent and a human metabolite. It is a tautomer of a [Pyr1]apelin-13(2+). | [Biological Activity]
(Pyr1)-Apelin-13the major apelin form in human plasma and heartcorresponds to Apelin-13 with posttranslationally modified pyroglutamyl (pGlupE) at the N-terminus instead of glutamine (GlnQ). (Pyr1)-Apelin-13 exhibits higher APJ agonist potency than Apelin-13 (EC50 = 0.30 vs. 0.37 nMrespectively; acidification induction in human APJ-expresing CHO cell cultures). (Pyr1)-Apelin-13 is reactive toward humanmurineratand bovine speciesand widely used for studyinhg APJ-mediated cellular and physiological functions both in cultures and in animals in vivo (via intraperitonealintravenousintrathecal injection). | [in vivo]
[Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction[1]. [Pyr1] apelin-13 (1, 5 μg) improves locomotor activity and reduces pain symptoms, cavity size and caspase-3 levels in rats. [Pyr1] apelin-13 (1, 5 μg) significantly increases thermal paw withdrawal latency. [Pyr1] apelin-13 in 5 μg dose also produces significant attenuation in paw withdrawal threshold compared to SCI animals from the second week post SCI[2]. | [storage]
Desiccate at -20°C |
|
|